Author

Jieyi Gu

Observed name: Gu, Jieyi

Institutions: China Pharmaceutical University, State Key Laboratory of Natural Medicine

Observed institutions: China Pharmaceutical University, State Key Laboratory of Natural Medicine, East China Normal University

OpenAlex ID: A5091389757

Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy

2018 · Erhao Zhang, Peiwei Yang, et al. · Journal of Hematology & Oncology · 104

Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors

2018 · Erhao Zhang, Jieyi Gu, et al. · Molecular Cancer · 99

Significantly increased anti‐tumor activity of carcinoembryonic antigen‐specific chimeric antigen receptor T cells in combination with recombinant human IL‐12

2019 · Xiaowei Chi, Peiwei Yang, et al. · Cancer Medicine · 75

Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide

2018 · Erhao Zhang, Jieyi Gu, et al. · Journal of Hematology & Oncology · 45

Predicting miRNA’s target from primary structure by the nearest neighbor algorithm

2009 · Kao Lin, Ziliang Qian, et al. · Molecular Diversity · 6

Works count: 9

Citation count: 329

H-index: 5

I10-index: 4